Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
Status:
Withdrawn
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
To test the patient's cancerous tumor to see if it has a FGFR mutation and, if so, to see how
their cancer responds to a treatment with the drug ponatinib as well as examine the side
effects caused by ponatinib.